Research Reports

Key takeaways

Board appointed John R. Palumbo, 75, effective April 10, 2026, on Nominating Committee recommendation.

Palumbo brings 40+ years healthcare experience, including IPOs, operational transformations at AmerisourceBergen and Allscripts.

Current boards include PM Pediatrics, Lucid Diagnostics (NASDAQ: LUCD), ivWatch, QLess; chairs Brado AI advisory.

Receives standard non-executive director fees; no other arrangements or disclosable transactions.

CEO Erez Raphael: Palumbo's relationships to accelerate partnerships and growth trajectory.

Press release issued April 13, 2026, as Exhibit 99.1.

Full analysis

The appointment of John R. Palumbo strengthens DarioHealth's board with extensive healthcare expertise, particularly relevant for scaling commercial partnerships in health systems, payers, and providers. His track record includes leading multibillion-dollar platforms at AmerisourceBergen, COO at Allscripts, and current roles at diagnostics and medtech firms like Lucid Diagnostics. Management views this as strategic for transitioning to a partner-led go-to-market model, with Palumbo's networks expected to drive momentum amid market undervaluation concerns. No special compensation or related-party issues disclosed.

DRIO · DarioHealth Corp.

Summary

Key takeaways

Full analysis